ATE79030T1 - Arzneimittel mit guter stabilitaet. - Google Patents

Arzneimittel mit guter stabilitaet.

Info

Publication number
ATE79030T1
ATE79030T1 AT89105625T AT89105625T ATE79030T1 AT E79030 T1 ATE79030 T1 AT E79030T1 AT 89105625 T AT89105625 T AT 89105625T AT 89105625 T AT89105625 T AT 89105625T AT E79030 T1 ATE79030 T1 AT E79030T1
Authority
AT
Austria
Prior art keywords
drug
good stability
microcrystalline cellulose
binder
pravastatin
Prior art date
Application number
AT89105625T
Other languages
English (en)
Inventor
Yatindra Mohan Joshi
Pierina Chiesa
Nemichand Bherulal Jain
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22643088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79030(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE79030T1 publication Critical patent/ATE79030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vending Machines For Individual Products (AREA)
  • Formation And Processing Of Food Products (AREA)
AT89105625T 1988-03-31 1989-03-30 Arzneimittel mit guter stabilitaet. ATE79030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/176,127 US5030447A (en) 1988-03-31 1988-03-31 Pharmaceutical compositions having good stability
EP89105625A EP0336298B1 (de) 1988-03-31 1989-03-30 Arzneimittel mit guter Stabilität

Publications (1)

Publication Number Publication Date
ATE79030T1 true ATE79030T1 (de) 1992-08-15

Family

ID=22643088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89105625T ATE79030T1 (de) 1988-03-31 1989-03-30 Arzneimittel mit guter stabilitaet.

Country Status (14)

Country Link
US (1) US5030447A (de)
EP (1) EP0336298B1 (de)
CN (1) CN1026861C (de)
AT (1) ATE79030T1 (de)
AU (1) AU624117B2 (de)
CA (1) CA1323836C (de)
CY (1) CY1675A (de)
DE (1) DE68902344T2 (de)
DK (1) DK173862B1 (de)
HK (1) HK40093A (de)
IE (1) IE62956B1 (de)
NZ (1) NZ228076A (de)
SG (1) SG107292G (de)
ZA (1) ZA891424B (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU221849B1 (hu) * 1991-12-12 2003-02-28 Novartis Ag. HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
EP0812195B1 (de) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
DE69625046T2 (de) * 1995-12-22 2003-04-10 Kowa Co., Ltd. Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
EP0839526A3 (de) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
DE19724123A1 (de) 1997-06-09 1998-12-10 Voith Sulzer Papiermasch Gmbh Vorrichtung und Verfahren zum Überführen eines Einfädelstreifens oder einer Materialbahn
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
HUP0100433A3 (en) * 1997-12-22 2003-01-28 Schering Corp Orally administrable solid ribavirin dosage forms and process for producing them
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
KR100281521B1 (ko) * 1998-03-31 2001-02-15 김종인 프라바스타틴나트륨이 함유된 약제 조성물
KR100554924B1 (ko) 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
US6232351B1 (en) * 1998-05-22 2001-05-15 Amway Corporation Co-processed botanical plant composition
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
KR100536783B1 (ko) 1998-07-28 2005-12-14 다케다 야쿠힌 고교 가부시키가이샤 급속 붕해성 고체 제제
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6391583B1 (en) * 1998-12-18 2002-05-21 Wisconsin Alumni Research Foundation Method of producing antihypercholesterolemic agents
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
EP1165141A2 (de) * 1999-03-31 2002-01-02 Abbott Laboratories Neue formulierungen mit lipid regulierenden wirkstoffen
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
ATE524163T1 (de) * 2000-04-10 2011-09-15 Teva Pharma Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
ATE418979T2 (de) 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
HRP20020950A2 (en) 2000-06-09 2004-12-31 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20020183383A1 (en) * 2001-02-27 2002-12-05 Rene Belder Pharmaceutical compositions
PL369268A1 (en) * 2001-03-27 2005-04-18 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
WO2003000239A1 (en) * 2001-06-21 2003-01-03 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions containing pravastatin
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
CA2447984A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US6967218B2 (en) 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (de) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
US20050089572A1 (en) * 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
US20050113577A1 (en) * 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
WO2004021973A2 (en) * 2002-09-03 2004-03-18 Biovail Laboratories Inc. Pravastatin pharmaceutical formulations and methods of their use
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
EP1961419B1 (de) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
NZ536273A (en) 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
EP1689383B1 (de) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
WO2006008757A2 (en) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Stabilized pharmaceutical compositions of pravastatin
EP1786414A4 (de) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc Neue pharmazeutische statin-zusammensetzungen und relevante behandlungsverfahren
CA2573316A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
CN100453116C (zh) * 2004-10-19 2009-01-21 上海中西制药有限公司 复方氨茶碱片剂及其制备方法
WO2006054308A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
KR20070085874A (ko) 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
US8722734B2 (en) 2005-03-02 2014-05-13 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin K
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP1911441A3 (de) * 2006-10-11 2008-08-06 Lupin Limited Farbstabile pharmazeutische Dosierungsformen mit kontrollierter Freigabe von HMG-COA-Reduktase-Hemmern, die frei von Alkalisierungs- oder Pufferagenzien sind
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2394643B1 (de) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Topiramat-Formulierungen mit verzögerter Freisetzung
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CA2681449A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5539221B2 (ja) 2007-12-21 2014-07-02 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
CN101732267B (zh) * 2008-11-14 2012-05-30 丽珠医药集团股份有限公司 普伐他汀钠片剂、其用途及其制备方法
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
WO2012002464A1 (ja) * 2010-06-30 2012-01-05 持田製薬株式会社 ω３脂肪酸の配合製剤
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9399064B2 (en) 2011-04-12 2016-07-26 Sawai Pharmaceutical Co., Ltd. Pitavastatin-containing preparation and method for producing same
EP2699567A1 (de) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
IN2013MU02470A (de) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923272A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
EP4076459B1 (de) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
JP2026509792A (ja) 2023-03-02 2026-03-25 カルツィムン ビオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング がん及び／又は急性炎症性疾患を診断するための手段及び方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
US4342767A (en) * 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4681759A (en) * 1985-05-08 1987-07-21 Ortho Pharmaceutical Corporation Rioprostil-PVP complex
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments

Also Published As

Publication number Publication date
ZA891424B (en) 1989-10-25
DK155689A (da) 1989-10-01
EP0336298B1 (de) 1992-08-05
AU624117B2 (en) 1992-06-04
CN1036508A (zh) 1989-10-25
NZ228076A (en) 1991-04-26
DK155689D0 (da) 1989-03-30
DE68902344T2 (de) 1993-01-07
CY1675A (en) 1993-10-10
JPH026406A (ja) 1990-01-10
HK40093A (en) 1993-04-30
CA1323836C (en) 1993-11-02
AU3027689A (en) 1989-10-05
EP0336298A1 (de) 1989-10-11
DK173862B1 (da) 2002-01-07
SG107292G (en) 1992-12-24
US5030447A (en) 1991-07-09
CN1026861C (zh) 1994-12-07
DE68902344D1 (de) 1992-09-10
IE62956B1 (en) 1995-03-08
IE890929L (en) 1989-09-30
JP2935220B2 (ja) 1999-08-16

Similar Documents

Publication Publication Date Title
DE68902344D1 (de) Arzneimittel mit guter stabilitaet.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DK0698389T3 (da) Matrix med reguleret frigivelse til farmaceutiske præparater
BR9810984A (pt) Composto de triazol, uso do mesmo, e, composição farmacêutica
AR064896A2 (es) Composicion farmaceutica no higroscopica
FI924451A7 (fi) Laite parannetun kudoshajoittamisen ja/tai hemostasian aikaansaamiseks i
DE69028109D1 (de) Medizinische beatmungsgeräte
DE3772924D1 (de) Gegen oxydierung und verfaerbung stabilisierte arzneimittelzubereitungen.
DK0724885T3 (da) Pernasal sammensætning og pernasalt præparat indeholdende dette
ATE239709T1 (de) Racemisches huperzin a
EP0601058A4 (de) Transdermale formulierungen zur prazosinverabreichung.
IT1228211B (it) Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
CO5031291A1 (es) Composicion farmaceutica
SE8804628D0 (sv) New compounds
AU2437388A (en) 2, 3-Dihydro-2, 2-dimethyl-3-hydroxy-6-(trifluoroalkoxy)-4- amino derivatives
AU7797787A (en) The use of 2',3'-dideoxycytidin-2'-ene(2',3'-dideoxy-2',3'- didehydrocytidine) in treating patients infected with retroviruses
DE3871791D1 (de) Verwendung von homo- und copolymeren des vinylalkohols zum tablettieren von wirkstoffen.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DE3867042D1 (de) Pharmazeutische praeparate.
AU5326190A (en) 2-substituted N,N'-ditrimethoxybenzoyl piperazines, and therapeutic compositions containing them
DK623984D0 (da) Farmaceutisk doseringsenhed
GR890100379A (el) Φαρμακευτικές συνθέσεις έχοντας καλή σταθερότητα.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
KR880002520A (ko) 망막증의 치료방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time